U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx Reminder Ads and Reminder Labeling - Name-Only Exemption
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f)
What is FDA Rx Reminder Ads and Reminder Labeling - Name-Only Exemption?
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning. Apply to name-only prescription drug ads, reminder labeling, promotional items and short digital units without risk information.
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-10-07
What does this rule require?
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
How can marketing teams comply?
Apply to name-only prescription drug ads, reminder labeling, promotional items and short digital units without risk information.
What is FDA Rx Reminder Ads and Reminder Labeling - Name-Only Exemption?
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Request a free compliance scan of your homepage and book a time with Warrant.